Jakarta, CNBC Indonesia – The Sinovac vaccine that comes to Indonesia has two forms, namely the finished vaccine and raw material. The price of the two is different, around US $ 13.3 or Rp.192 thousand per dose.
This was conveyed by the Managing Director of Bio Farma, Honesti Basyir, when buying 3 million doses of Sinovac vaccine, the price per dose is US $ 17 or Rp.245 thousand. But he said negotiations were going on to get several hundred thousand doses eventually free.
“So that the final price is around US $ 13.3 dollars (Rp 192 thousand), that’s when the vaccine imports are finished,” said Honesti, in the RDP of the House of Representatives Commission VI with PT Bio Farma, PT Kimia Farma and PT Indofarma which was broadcast live on the YouTube right of Commission VI. DPR RI, Monday (29/3/2021).
Meanwhile, when the Sinovac vaccine was imported, it was in bulk form or raw materials, the price was US $ 10.9 or Rp157 thousand. That way the purchase of bulk vaccine is cheaper, around US $ 3 per dose.
Apart from being efficient, according to Honesti, Indonesia also gets technology transfer if it produces its own vaccines. “There is efficiency that we get, besides that there is a transfer of technology for self-production, which is good in the future,” he said.
The process of determining the price is a recommendation from Biofarma. Derived from the cost of the product and then added other costs such as distribution, packaging, operations resulting in Cost of Goods Sold or COGS.
After the HPP (cost of goods sold) is obtained, it is verified by the Financial and Development Supervisory Agency (BPKP). Finally, the Ministry of Health set the margin as the basis for the contract with Bio Farma.
“HPP from us and BPKP then given to the Ministry of Health,” said Honesti.
However, Honesti refused to disclose the margin amount at the meeting. He asked to submit it in writing to Commission VI. “The contact from the Ministry of Health is the point of delivery in the province. From the percentage of the margin, we just write that it is not good to talk here,” he explained.
(roy/roy)
– .
